Ability to Compound Low- and Medium-Risk CSPs Ability to Compound Low- and Medium-Risk CSPs Executive Summary: Medical Center A was highly reliant on outside compounding pharmacies for the production of sterile compounds. In response to the closure of Compounding Company A and due to the increased regulatory scrutiny of sterile compounding, the majority of sterile compounds to be used at our medical center will now be prepared in-house using our Clean Room. This transition requires operational changes additional labor, sterility testing by an outside laboratory, and the addition of refrigeration storage in many of our intensive care units. Total operating expenses will decrease from what was $1,105,515 in annual expenses in FY12 to a total annualized operating cost of $976,067 for an annualized savings of $129,448. One-time expenses of $71,700 are needed in the
Ability to Compound Low- and Medium-Risk CSPs Ability to Compound Low- and Medium-Risk CSPs Executive Summary: Medical Center A was highly reliant on outside compounding pharmacies for the production of sterile compounds. In response to the closure of Compounding Company A and due to the increased regulatory scrutiny of sterile compounding, the majority of sterile compounds to be used at our medical center will now be prepared in-house using our Clean Room. This transition requires operational changes additional labor, sterility testing by an outside laboratory, and the addition of refrigeration storage in many of our intensive care units. Total operating expenses will decrease from what was $1,105,515 in annual expenses in FY12 to a total annualized operating cost of $976,067 for an annualized savings of $129,448. One-time expenses of $71,700 are needed in the
Single%20Hospital%20Sterile%20Product%20Preparation%20Business%20Case.docx